Form 4: Cargo Therapeutics CFO Anup Radhakrishnan Executes Stock Option and Sells Shares

Anup Radhakrishnan, CFO of Cargo Therapeutics, exercised stock options and sold shares on September 18, 2024, according to a Form 4 filing with the SEC.

Summary

• Anup Radhakrishnan, the Chief Financial Officer of CARGO Therapeutics, Inc., executed a transaction involving the company's stock on September 18, 2024.
• Radhakrishnan exercised a stock option to acquire 1,600 shares of common stock at a price of $5.03 per share.
• Simultaneously, Radhakrishnan sold 1,600 shares of common stock at a weighted average price of $25.2825 per share, with individual trades ranging from $25.25 to $25.44.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 28, 2024.
• Following these transactions, Radhakrishnan directly owns 6,446 shares of Cargo Therapeutics common stock and holds options for 53,180 shares.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing insider transactions, which is neutral in sentiment.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions. It provides transparency into the trading activities of company executives, which is a standard practice in the biotech industry.

Comparison to Industry Standards

• Executive compensation packages in the biotechnology industry often include stock options as incentives.
• The vesting schedule of 25% after one year and then monthly is a common vesting schedule.
• Rule 10b5-1 trading plans are frequently used by executives to avoid accusations of insider trading when selling company stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they involve the sale of shares by a company executive.
• The transactions are unlikely to significantly affect employees, customers, suppliers, or creditors.

Key Dates